Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Purine-processing enzymes represent a broad category of enzymes involved in the de novo synthesis, salvage, and degradation of purine nucleotides, which are essential for DNA and RNA production, cellular energy (ATP), and signaling (GTP) [1, 12]. This group includes critical therapeutic targets such as xanthine oxidase, which catalyzes the final steps of purine catabolism into uric acid, and inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme in guanine nucleotide synthesis [7, 13]. Dysregulation of these pathways is central to several diseases; for instance, overactivity of xanthine oxidase leads to hyperuricemia and gout, while accelerated purine synthesis supports the rapid proliferation of cancer cells [4, 13]. Drugs targeting these enzymes are widely used in clinical practice: xanthine oxidase inhibitors like allopurinol treat gout, IMPDH inhibitors like mycophenolate mofetil serve as potent immunosuppressants, and purine antimetabolites like 6-mercaptopurine are staples in leukemia chemotherapy [5, 7, 9]. Because these enzymes are fundamental to cell survival and immune function, therapeutic intervention often requires careful monitoring for side effects such as myelosuppression and hepatotoxicity [5, 13].
Purine-processing enzymes are targeted through several distinct mechanisms: xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) block the production of uric acid to treat gout [7, 13]; inosine monophosphate dehydrogenase (IMPDH) inhibitors (e.g., mycophenolate mofetil, ribavirin) reduce guanosine nucleotide levels for immunosuppression or antiviral effects [7, 9]; adenosine deaminase (ADA) inhibitors (e.g., pentostatin) cause toxic accumulation of deoxyadenosine in lymphoid cells [5, 10]; and purine antimetabolites (e.g., 6-mercaptopurine, fludarabine) act as false substrates that inhibit de novo synthesis or disrupt DNA/RNA polymerization [5, 6, 9].
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purine-processing enzymes.